Sophiris Bio (OTCMKTS:SPHS) and Xilio Therapeutics (NASDAQ:XLO) Head-To-Head Contrast

Xilio Therapeutics (NASDAQ:XLO) and Sophiris Bio (OTCMKTS:SPHS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation.

Valuation and Earnings

This table compares Xilio Therapeutics and Sophiris Bio”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$9.27 million	6.30	-$76.40 million	($0.84)	-1.34
Sophiris Bio	N/A	N/A	N/A	N/A	N/A

Sophiris Bio has lower revenue, but higher earnings than Xilio Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Xilio Therapeutics and Sophiris Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	0	0	1	0	3.00
Sophiris Bio	0	0	0	0	0.00

Xilio Therapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 254.30%. Given Xilio Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Xilio Therapeutics is more favorable than Sophiris Bio.

Volatility and Risk

Xilio Therapeutics has a beta of -0.27, suggesting that its share price is 127% less volatile than the S&P 500. Comparatively, Sophiris Bio has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500.

Institutional and Insider Ownership

54.3% of Xilio Therapeutics shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by company insiders. Comparatively, 4.5% of Sophiris Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Xilio Therapeutics and Sophiris Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	N/A	-211.50%	-80.31%
Sophiris Bio	N/A	N/A	N/A

Summary

Xilio Therapeutics beats Sophiris Bio on 6 of the 9 factors compared between the two stocks.

About Xilio Therapeutics

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

About Sophiris Bio

Sophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA.